Financial Performance and Market Position - The backlog as of December 31, 2022, was approximately €957.0 million, an increase from €880.0 million as of December 31, 2021, indicating potential future revenue growth [61]. - The company’s estimates of its addressable market may be based on assumptions that could prove inaccurate, potentially limiting revenue opportunities [60]. - 44.26% of revenues in 2022 derived from the top ten customers, with no individual customer representing more than 10.0% of revenues [88]. - The company is pursuing strategies to expand global market position and increase investments in R&D to address unmet market needs [85]. - The company plans to expand its global market position in drug containment solutions and drug delivery systems, with a focus on increasing investments in research and development [92]. Operational Risks and Challenges - The company faces significant risks related to technological obsolescence and competition, which could adversely affect its market position and financial performance [48]. - Significant interruptions in operations could harm the company's financial condition and results of operations [51]. - The company must continuously develop new products and enhance existing ones to remain competitive in a rapidly changing market [55]. - The company faces intense competition from both smaller specialized companies and large multinationals, which may impact future sales and earnings [82]. - The company may experience increased costs and operational disruptions if acceptable supplier alternatives are not found [73]. Supply Chain and Production - The company is highly dependent on maintaining relationships with suppliers and service providers, which is critical for its operational success [51]. - Significant reliance on suppliers for high-quality materials and energy supply, with potential adverse effects on gross margins if terms change [68]. - The company increased production capacity to support COVID-19 vaccination efforts, providing glass vials and syringes for approximately 90% of currently marketed vaccine programs [76]. - The company is establishing new manufacturing plants for EZ-Fill® products in Indiana (U.S.), Zhangjiagang (China), and Latina (Italy), with a strong emphasis on biologics and vaccines [92]. Regulatory and Compliance Risks - The company is subject to a variety of laws and regulations, including health and safety, environmental protection, and the handling of hazardous substances, which could significantly affect its operations if regulatory controls were to increase [120]. - The potential restriction or ban on the use of ethylene oxide, a key sterilizing agent, could require the company to identify new sterilizing agents, negatively impacting its financial condition and results of operations [120]. - The company is exposed to regulatory risks related to anti-corruption and trade control laws, which could result in civil and criminal penalties if compliance is not maintained [133]. - The company faces increased scrutiny from Italian tax authorities, which may lead to tax audits and significant liabilities [152]. Economic and Geopolitical Factors - The company faces macro-economic risks, particularly in Italy, where high sovereign debt and political instability could adversely affect business operations [115]. - The ongoing conflict between Russia and Ukraine has led to increased operational costs and potential disruptions, particularly affecting gas and electricity prices [113]. - The deterioration of sovereign debt in several countries has exacerbated the global economic crisis, particularly affecting the Eurozone, which could materially impact the company's business and financial condition [118]. Intellectual Property and Legal Risks - The company may face challenges in maintaining and enforcing its patent rights, which could limit its competitive position in the market [186]. - The company may incur substantial costs and delays due to third-party patent infringement claims, affecting its product development and commercialization efforts [197]. - The company faces potential legal challenges regarding patent validity, which could result in loss of patent protection and allow competitors to commercialize its technology without compensation [202]. - The company relies on external law firms for patent maintenance, and failure to comply with patent agency requirements could lead to reduced protection or loss of patents [204]. Shareholder and Corporate Governance - The concentrated voting power of Stevanato Holding S.r.l. allows it to control significant corporate decisions, which may not align with the interests of other shareholders [223]. - Future sales of a substantial number of shares could negatively impact the market price of the company's ordinary shares [226]. - The company is incorporated under Italian law, which may result in different shareholder rights compared to typical U.S. corporations [229]. - The company has historically paid dividends over the last three years, but future declarations are uncertain and depend on the Board's review of financial performance and strategy [232]. Cybersecurity and Data Privacy - Cybersecurity risks could lead to reputational damage and regulatory penalties, impacting business operations [164]. - The company faces significant operational costs and potential fines due to compliance with data privacy and security regulations, which could adversely affect its financial condition and results of operations [174]. Employee and Operational Structure - The company employs approximately 5,260 employees as of December 31, 2022, with 51% based in Italy and 10% in both Mexico and Germany [147]. - The obligations of being a public company increase legal and financial compliance costs, which may divert management's attention from growth strategies [240].

Stevanato Group S.p.A. (NYSE:STVN) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Lisa Miles - SVP Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Capital Markets Patrick Donnelly - Citi Derik De Bruin - Bank of America Tim Daley - Wells Fargo John Sourbeer - UBS David Windley - Jefferies Madeline Mollman - William Blair Drew Ranieri - Mor ...

Exhibit 99.1 For the fourth quarter of 2022, gross profit margin increased 290 basis points to 34.3% driven by higher revenue, the mix shift to high value solutions, better leverage of fixed costs, and the recovery of inflationary costs, while operating profit margin of 21.6% included a benefit of €3.0 million related to a joint development project. Full Year 2022 Results Revenue for fiscal 2022 increased 17% to €983.7 million (approximately 13% on a constant currency basis), compared with the same period l ...

Stevanato Group Q4 and Full Year 2022 Financial Results March 2nd, 2023 Safe Harbor Statement Forward-Looking Statements This presentation may include forward-looking statements. The words "expect," "growth", "deliver" "drive," "create," "accelerating," "sustained," "believe," "building," "future," "well positioned," "continues," "remain," "estimate," and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding th ...

Financial Data and Key Metrics Changes - For Q3 2022, revenue increased by 14% to €245.3 million compared to the previous year, driven by growth in the Biopharmaceutical and Diagnostic Solutions segment and favorable currency translation [24] - Adjusted EBITDA margin was reported at 26.8% [26] - Gross profit margin increased by 210 basis points to 31.6%, primarily due to a strategic shift towards high-value solutions [25] - Net profit for Q3 2022 was €36.3 million, or €0.14 diluted earnings per share [26] Business Line Data and Key Metrics Changes - Revenue from the Biopharmaceutical and Diagnostic Solutions segment increased by 20% to €207.1 million, with high-value solutions growing by 54% to €74.4 million [27] - The Engineering segment saw a revenue decrease of 9% to €38.2 million, attributed to project timing [29] Market Data and Key Metrics Changes - New order intake for Q3 totaled €247 million, with a year-over-year decrease due to a drop in COVID-19 orders; excluding COVID, new order intake increased by approximately 6% [14] - Committed backlog increased by 21% to just over €1 billion [14] Company Strategy and Development Direction - The company is focused on advancing global capacity expansion, growing the mix of high-value solutions, investing in R&D, and building a multi-year pipeline of new opportunities [36] - The introduction of the EZ-Fill Smart platform aims to enhance productivity and reduce contamination risks, aligning with the company's long-term strategy of providing integrated solutions [15][18] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about demand trends, particularly in the context of the growing pipeline for new treatments, with approximately 60% tied to injectable delivery [8] - The company is proactively managing inflationary pressures and supply chain complexities, with expectations of continued strong demand for high-value solutions [13][14] Other Important Information - The company has a strong balance sheet with a positive net financial position of €49.6 million and cash and cash equivalents of €259.9 million as of September 30 [31] - Capital expenditures for Q3 were €71.1 million, reflecting ongoing investments in strategic global expansion plans [31] Q&A Session Summary Question: Update on COVID revenue contribution - Management confirmed that COVID-related revenue is still expected to be around 10% for the year [43] Question: Demand for non-COVID products - Management indicated that demand remains strong, with an increase in order intake year-over-year, particularly for high-value solutions [46] Question: EZ-Fill Smart collaboration structure - Revenue from EZ-Fill products will be independent, with potential shared licensing fees if technology is licensed to third parties [53] Question: Margin dynamics with high-value solutions - Management stated that margins for COVID and non-COVID products are similar, and they are successfully replacing COVID orders with strong demand for other therapeutic areas [65] Question: Capacity expansion timelines - Construction of the Indiana facility is on track, with no anticipated delays in revenue recognition [72] Question: Pricing and inflationary cost pushback - Management noted that they have passed on costs to customers but are focused on long-term relationships rather than immediate gains [74]

Stevanato Group S.p.A. (NYSE:STVN) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Lisa Miles - Investor Relations Franco Stevanato - Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Justin Lin - William Blair Derik De Bruin - Bank of America Patrick Donnelly - Citi Steven Couche - Jefferies John Sourbeer - UBS Operator Good afternoon. This is the Chorus Call Conference operator. Welcome ...

Second Quarter 2022 Financial Results August 4, 2022 Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. ("we", "our", "us", "Stevanato Group" or the "Company"). These forward-looking statements include, or may include, words such as "plan", "advancing", "emerging", "opportunities", "increasing", "trends", "advancement" ...

Financial Data and Key Metrics Changes - For Q1 2022, revenue grew by 10% to €212.1 million, or 8% on a constant currency basis, driven by growth in both segments [27] - Adjusted EBITDA was €54 million with an adjusted EBITDA margin of 25.5% [30] - Net profit for the quarter was €27.8 million, or €0.10 diluted earnings per share, with adjusted net profit at €28.6 million and adjusted diluted EPS at €0.11 [30] - Gross profit margin was 31.8%, benefiting from a higher mix of high-value solutions, but impacted by production slowdowns and inflationary costs [29] Business Line Data and Key Metrics Changes - BDS segment revenue increased by 7% to €172.4 million, with high-value solutions growing by 37% year-over-year to €61.5 million [31] - Engineering segment revenue grew by 23% to €39.6 million, driven by strong demand for glass forming and visual inspection machines [33] - The mix of high-value solutions increased to 29% of total revenue, up from 23% last year [28] Market Data and Key Metrics Changes - Europe remains the largest market, contributing 58.5% of revenue, followed by North America at 25% and Asia Pacific at 13.4% [89] - New order intake increased by 29% to approximately €324 million, leading to a committed backlog of approximately €992 million, up from €665 million last year [13] Company Strategy and Development Direction - The company is focused on expanding its capacity for high-value solutions to meet robust customer demand, with significant investments in the U.S. and China [20][22] - Strategic partnerships, such as with Owen Mumford for auto-injectors, are aimed at enhancing integrated solutions across segments [17] - The company aims to increase the mix of high-value solutions to the mid-30% range by 2026 [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledges challenges from inflation and supply chain disruptions but remains optimistic about strong demand trends [23][24] - The company expects to maintain its full-year guidance despite lower-than-expected revenue from COVID-related products [38] - Management emphasizes a strong backlog and positive trends in various therapeutic areas, indicating confidence in future growth [47][51] Other Important Information - The Board has recommended a cash dividend of €13.5 million, subject to shareholder approval [9][10] - Capital expenditures for Q1 2022 were €53.8 million, reflecting ongoing investments in strategic growth initiatives [35] Q&A Session Summary Question: What is the embedded expectation for organic constant currency growth in the guidance? - Management expects double-digit organic growth without considering foreign exchange effects [44] Question: Are customers canceling orders or pushing them to 2023? - There have been changes in customer forecasts for COVID business, but overall demand remains strong in other therapeutic areas [50][51] Question: What is driving the strong demand for high-value solutions? - Strong demand is noted for syringes in Nexa and Alba configurations, with a focus on converting the market from glass vials to EZ-fill vials [54][55] Question: Can you provide insights on backlog growth and customer ordering patterns? - The backlog is driven by long-term demand rather than temporary spikes, with strong visibility for 2022 and beyond [78][80] Question: What updates are there on capital expansion in Italy? - The company continues to invest in Italy, with additional capacity being released regularly [92]

Stevanato Group S.p.A. (NYSE:STVN) Q4 2021 Results Earnings Conference Call March 8, 2022 8:30 AM ET Company Participants Lisa Miles - Head of Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer and Chief Operating Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants David Windley - Jefferies Paul Knight - KeyBanc Capital Markets Derik De Bruin - Bank of America Elizabeth Speyer - Citigroup Timothy Daley - Wells Fargo Drew Ranieri - Morgan ...

Fourth Quarter and Year End 2021 Financial Results March 8, 2022 Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements which include, or may include, words such as "future "expect", "expected", "progress", "intended", "will", "planned", "on track", "targeted", "estimate", "estimating", "anticipate", "anticipated", "may", "consider", "believe" and other similar terminology. Forward-looking statements contained in this prospectus include, but are not li ...